{"id":19667,"date":"2022-11-11T17:54:55","date_gmt":"2022-11-11T12:24:55","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=19667"},"modified":"2022-11-11T17:54:56","modified_gmt":"2022-11-11T12:24:56","slug":"emerging-therapies-for-cutaneous-t-cell-lymphoma-treatment","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-cutaneous-t-cell-lymphoma-treatment","title":{"rendered":"How Will the Emerging Therapies for Cutaneous T-cell Lymphoma Reshuffle its Treatment Landscape"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a00c85290124\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a00c85290124\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-cutaneous-t-cell-lymphoma-treatment\/#Emerging_Therapies_in_the_Cutaneous_T-cell_Lymphoma_Market\" >Emerging Therapies in the Cutaneous T-cell Lymphoma Market&nbsp;<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-cutaneous-t-cell-lymphoma-treatment\/#Drug_SGX301\" >Drug: SGX301<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-cutaneous-t-cell-lymphoma-treatment\/#Drug_Pembrolizumab\" >Drug: Pembrolizumab<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-cutaneous-t-cell-lymphoma-treatment\/#Drug_Resminostat\" >Drug: Resminostat<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-cutaneous-t-cell-lymphoma-treatment\/#Drug_CD11301\" >Drug: CD11301<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-cutaneous-t-cell-lymphoma-treatment\/#Drug_EQ101\" >Drug: EQ101<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-cutaneous-t-cell-lymphoma-treatment\/#What_Lies_ahead\" >What Lies ahead?\u00a0<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-cutaneous-t-cell-lymphoma-treatment\/#FAQs\" >FAQs<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>Cutaneous T-cell lymphoma (CTCLs) characterized by cutaneous infiltration of malignant monoclonal T-lymphocytes is a rare lymphoma affecting around 6.4 cases per million individuals every year. The total <a href=\"https:\/\/www.delveinsight.com\/report-store\/cutaneous-t-cell-lymphoma-ctcl-epidemiology-forecast\">incident population of Cutaneous T-cell lymphoma<\/a> in the 7MM was around<strong> 7.5K in 2021<\/strong>, with the US accounting for the highest patient share\/incidence. CTCL is further characterized by mycosis fungoides (MF), S\u00e9zary syndrome, and primary cutaneous peripheral T cell lymphoma, while the most common CTCL type is mycosis fungoides.&nbsp;<\/p>\n\n\n\n<p>Various treatment options available for CTCL treatment depend upon the severity of the disease or the stage of cancer. It also depends upon whether the disease&nbsp; involves the lymph nodes, the blood or other organs in the body, type, extent of skin lesions present (patches, plaques, or&nbsp; tumors), number of S\u00e9zary cells in the blood, and transformation to large cell type or folliculotropic mycosis fungoides.<\/p>\n\n\n\n<p>Currently, the <a href=\"https:\/\/www.delveinsight.com\/blog\/cutaneous-t-cell-lymphoma-treatment-market\">FDA-approved drugs available in the CTCL market<\/a> for the treatment of mycosis fungoides or S\u00e9zary syndrome include <strong>Istodax (romidepsin), Valchlor (mechlorethamine), Uvadex&nbsp; (methoxsalen), Targretin (bexarotene), Adcetris (brentuximab vedotin) and Zolinza (vorinostat)<\/strong>.&nbsp;<\/p>\n\n\n\n<p>Moreover, several pharma giants are working on CTCL treatment therapies, including, <strong>Soligenix, Merck Sharp &amp; Dohme Corp, Elorac,&nbsp; Innate Pharma, Viridian Therapeutics, Sorrento Therapeutics, Bio-Path Holdings, Legend Biotech, Genzada Pharmaceuticals, VidacPharma, Bioniz Therapeutics,&nbsp; Otsuka Pharmaceutical,&nbsp; Hoffmann-La Roche, BioInvent International AB, Scopus BioPharma, Codiak BioSciences<\/strong>, and are working on developing effective cures for CTCL to cater to the needs of the patients.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Emerging_Therapies_in_the_Cutaneous_T-cell_Lymphoma_Market\"><\/span><strong>Emerging Therapies in the Cutaneous T-cell Lymphoma Market&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The <a href=\"https:\/\/www.delveinsight.com\/report-store\/cutaneous-t-cell-lymphoma-ctcl-pipeline-insight\">CTCL pipeline<\/a> is robust, with several therapies in the mid-stage of clinical development. The anticipated launch of emerging therapies such as <strong>SGX301,<\/strong> <strong>Pembrolizumab, Resminostat, CD11301, and EQ101&nbsp; <\/strong>will boost the CTCL market growth in the coming years. A detailed assessment of some of these therapies is given below::&nbsp;&nbsp;&nbsp;<\/p>\n\n\n\n<figure class=\"wp-block-image size-full is-resized\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/11\/11175232\/Emerging-Therapies-for-Cutaneous-T-cell-Lymphoma.png\" alt=\"CTCL Pipeline Therapies\" class=\"wp-image-19672\" width=\"883\" height=\"320\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/11\/11175232\/Emerging-Therapies-for-Cutaneous-T-cell-Lymphoma.png 883w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/11\/11175232\/Emerging-Therapies-for-Cutaneous-T-cell-Lymphoma-300x109.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/11\/11175232\/Emerging-Therapies-for-Cutaneous-T-cell-Lymphoma-150x54.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/11\/11175232\/Emerging-Therapies-for-Cutaneous-T-cell-Lymphoma-768x278.png 768w\" sizes=\"(max-width: 883px) 100vw, 883px\" \/><figcaption><strong>Promising Therapies in the Cutaneous T-cell Lymphoma Pipeline<\/strong><\/figcaption><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Drug_SGX301\"><\/span><strong>Drug: SGX301<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>Company: Soligenix&nbsp;<\/strong><\/p>\n\n\n\n<p><strong>Phase: Phase III<\/strong><\/p>\n\n\n\n<p><strong>MoA: Cell death stimulants; HSP90 heat-shock protein inhibitors; Immunosuppressants; Photosensitisers; Protein kinase C inhibitors; Singlet oxygen stimulants<\/strong><\/p>\n\n\n\n<p>SGX301 by Soligenix is a first-in-class photodynamic therapy that majorly overcomes the risks of already preferred PDT-UVA therapies and has received Fast-track and Orphan Drug designation from the USFDA.&nbsp;<\/p>\n\n\n\n<p>Recently, Soligenix announced positive topline results for its Phase III (NCT02448381) FLASH Trial. Follow-up visits were completed in Q4 2020, and data lock and the final analysis remain ongoing.&nbsp;<\/p>\n\n\n\n<p>Soligenix is preparing to commercialize SGX301 in the US and entered into a strategic partnership with <strong>Daavlin<\/strong> for the supply and distribution of&nbsp; SGX301 companion light devices to treat<a href=\"https:\/\/www.delveinsight.com\/blog\/cutaneous-t-cell-lymphoma-treatment-market\"> cutaneous T-cell lymphoma<\/a>. In 2021, the drug received conditional FDA acceptance of the proposed brand name<strong> HyBryte<\/strong> for SGX301 in the CTCL treatment market.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Drug_Pembrolizumab\"><\/span><strong>Drug: Pembrolizumab<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>Company: Merck &amp; Co.&nbsp;<\/strong><\/p>\n\n\n\n<p><strong>Phase:&nbsp; Phase II<\/strong><\/p>\n\n\n\n<p><strong>MoA: Programmed cell death-1 receptor antagonists<\/strong><\/p>\n\n\n\n<p>Pembrolizumab developed by Merck &amp; Co. is an anti-programmed death receptor-1 (PD-1) therapy that works by increasing the ability of the body\u2019s immune system to help detect and fight tumor cells. It is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1, and PD-L2, thereby activating T lymphocytes which may affect both tumor cells and healthy cells.&nbsp;<\/p>\n\n\n\n<p>Currently, this drug is in Phase II (NCT03385226) to assess the effect of pembrolizumab combined with radiotherapy in patients with relapsed, refractory, specified stages of Cutaneous T-cell Lymphoma (CTCL) Mycosis Fungoides (MF)\/Sezary Syndrome (SS).<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-drug-resminostat\"><span class=\"ez-toc-section\" id=\"Drug_Resminostat\"><\/span><strong>Drug: Resminostat<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>Company: 4SC AG<\/strong><\/p>\n\n\n\n<p><strong>Phase:&nbsp; Phase II<\/strong><\/p>\n\n\n\n<p><strong>MoA: Histone deacetylase inhibitors<\/strong><\/p>\n\n\n\n<p>Resminostat developed by 4SC AG, is an orally administered histone deacetylase (HDAC) inhibitor that potentially represents a novel therapy for a broad spectrum of oncology indications, both in monotherapy and particularly in combination with other <a href=\"https:\/\/www.delveinsight.com\/report-store\/oncology-drugs-market\">anti-cancer drugs<\/a>.&nbsp;<\/p>\n\n\n\n<p>The clinical development of resminostat is currently focused on cutaneous T-cell lymphoma (CTCL).<\/p>\n\n\n\n<p>Currently, this drug is in Phase II (RESMAIN) (NCT02953301) to trial evaluate it for maintenance treatment of patients with advanced stage (Stage IIb-IVb) mycosis fungoides (MF) or s\u00e9zary syndrome (SS) that have achieved disease control with systemic therapy.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Drug_CD11301\"><\/span><strong>Drug: CD11301<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>Company: Galderma<\/strong><\/p>\n\n\n\n<p><strong>Phase:&nbsp; Phase II<\/strong><\/p>\n\n\n\n<p><strong>MoA: Immunostimulants; Interferon alpha stimulants; Toll-like receptor 7 agonists; Toll-like receptor 8 agonists<\/strong><\/p>\n\n\n\n<p>Galderma\u2019s CD11301 has completed the Phase II (NCT03292406) study for CTCL treatment. It is a topical gel containing the Toll-like receptor (TLR) agonist resiquimod, imidazoquinolinamines, with potential immunomodulating activity. Upon topical application, the resiquimod gel CD11301 binds to TLR7 and 8, which are found mainly on dendritic cells (DCs), macrophages, and B lymphocytes. It activates the TLR&nbsp; signaling pathway, which results in the induction of the nuclear translocation of transcription activator nuclear factor kappa-B (NF-kB) and the activation of other transcription factors. Subsequently, NF-kB-dependent gene expression is induced, and cytokine production increases, especially interferon-alpha (INF-a), which enhances T-helper 1 (Th1) immune responses. In addition, topical application of resiquimod appears to activate epidermal Langerhans cells, leading to enhanced activation of T lymphocytes.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Drug_EQ101\"><\/span><strong>Drug: EQ101<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>Company: Equillium Bio.<\/strong><\/p>\n\n\n\n<p><strong>Phase:&nbsp; Phase I\/II&nbsp;<\/strong><\/p>\n\n\n\n<p><strong>MoA: Interleukin 15 receptor antagonists; Interleukin 2 receptor antagonists; Interleukin 9 receptor antagonists<\/strong><\/p>\n\n\n\n<p>Equillium Bio.\u2019s EQ101, formerly known as <strong>BNZ-1,<\/strong> is a first-in-class, tri-specific inhibitor of IL-2, IL-9, and IL-15, three inflammatory cytokines implicated in multiple diseases. It has demonstrated clinical proof-of-concept as a novel cytokine inhibitor through a completed Phase I\/II (NCT03239392) study in the CTCL treatment market.<\/p>\n\n\n\n<p>BNZ-1 is currently formulated for intravenous administration, with subcutaneous formulation development underway. It has received orphan drug designation from EC and FDA.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_Lies_ahead\"><\/span><strong>What Lies ahead?\u00a0<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The current CTCL treatment options in the market have been a constant challenge for the past 20 years. Apart from that, the newer therapies are constantly changing, adding to the challenges. The hunt to look for improved and better CTCL treatment options has constantly been emerging to land upto treatment entities that possess better efficacy and have a safer therapeutic window to fulfill unmet medical needs.&nbsp;<\/p>\n\n\n\n<p>The most common <a href=\"https:\/\/www.delveinsight.com\/report-store\/cutaneous-t-cell-lymphoma-ctcl-market\">CTCL treatment drug options<\/a> that are currently being examined include fusion molecules like denileukin diftitox, topical retinoids, interleukin-2, interleukin-12, and pegylated interferon. A few more therapies that show clinical potential include gemcitabine, Pegylated liposomal doxorubicin, and chlorodeoxyadenosine. The remaining therapies that can be used for cutaneous T-cell lymphoma treatment include vaccines and monoclonal antibodies. The newer emerging therapies have the potential to overcome the downsides of the currently existing therapies and can possibly improve the health quality and decrease the cutaneous T cell lymphoma fatality rate.&nbsp;<\/p>\n\n\n\n<p>Furthermore, the CTCL treatment market is posing newer opportunities for several new market players as there is no existing curative treatment and the disease has a high tendency to resist newer developed therapies.&nbsp;<\/p>\n\n\n\n<figure class=\"wp-block-image size-large is-resized\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/cutaneous-t-cell-lymphoma-ctcl-pipeline-insight\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/11\/11175137\/CTCL-Pipeline-Assessment-1024x256.png\" alt=\"CTCL Pipeline Assessment\" class=\"wp-image-19671\" width=\"1024\" height=\"256\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/11\/11175137\/CTCL-Pipeline-Assessment-1024x256.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/11\/11175137\/CTCL-Pipeline-Assessment-300x75.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/11\/11175137\/CTCL-Pipeline-Assessment-150x38.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/11\/11175137\/CTCL-Pipeline-Assessment-768x192.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/11\/11175137\/CTCL-Pipeline-Assessment-1536x384.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/11\/11175137\/CTCL-Pipeline-Assessment-1568x392.png 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/11\/11175137\/CTCL-Pipeline-Assessment.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FAQs\"><\/span><strong>FAQs<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<div class=\"schema-faq wp-block-yoast-faq-block\"><div class=\"schema-faq-section\" id=\"faq-question-1668168417143\"><strong class=\"schema-faq-question\"><strong>What is Cutaneous T-cell lymphoma?\u00a0<\/strong><\/strong> <p class=\"schema-faq-answer\">Cutaneous T-cell lymphoma (CTCL) is a rare type of blood cancer. It begins in a type of white blood cell called the T-lymphocyte (T-cell). T-cells help prevent infections and other diseases.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1668168427312\"><strong class=\"schema-faq-question\"><strong>What are the CTCL treatment options?\u00a0<\/strong><\/strong> <p class=\"schema-faq-answer\">CTCL treatment options include topical chemotherapy, radiation therapy, photo-chemotherapy, vitamin A derivatives (retinoids), and chemotherapy. These treatments may be used alone or in varied combinations.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1668168441451\"><strong class=\"schema-faq-question\"><strong>What is the cutaneous T-cell lymphoma market size?\u00a0<\/strong><\/strong> <p class=\"schema-faq-answer\">In the seven major geographies, the cutaneous T-cell lymphoma market size is estimated to be approximately<strong> <\/strong>USD 399 million in 2021.<strong>\u00a0<\/strong><\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1668168451041\"><strong class=\"schema-faq-question\"><strong>Are any FDA-approved drugs available in the cutaneous T-cell lymphoma market?<\/strong><\/strong> <p class=\"schema-faq-answer\">Currently, the FDA-approved drugs available in the cutaneous T-cell lymphoma market include SGX301 (Soligenix), WP1220 (Moleculin Biotech), and Lacutamab (Innate Pharma).<\/p> <\/div> <\/div>\n","protected":false},"excerpt":{"rendered":"<p>Cutaneous T-cell lymphoma (CTCLs) characterized by cutaneous infiltration of malignant monoclonal T-lymphocytes is a rare lymphoma affecting around 6.4 cases per million individuals every year. The total incident population of Cutaneous T-cell lymphoma in the 7MM was around 7.5K in 2021, with the US accounting for the highest patient share\/incidence. CTCL is further characterized by [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":19670,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[19798,19921,19799,17947,4968,19919,19920],"industry":[17225],"therapeutic_areas":[17233,17228,17234],"class_list":["post-19667","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-ctcl","tag-ctcl-drugs","tag-ctcl-treatment","tag-cutaneous-t-cell-lymphoma-treatment","tag-cutaneous-t-cell-lymphoma","tag-cutaneous-t-cell-lymphoma-pipeline","tag-cutaneous-t-cell-lymphoma-therapies","industry-pharmaceutical","therapeutic_areas-hematological-disorders","therapeutic_areas-oncology","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Promising Therapies for Cutaneous T-cell Lymphoma Treatment<\/title>\n<meta name=\"description\" content=\"Over 25+ leading giants are currently evaluating their lead assets in various stages of clinical development to improve therapeutic space.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-cutaneous-t-cell-lymphoma-treatment\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Promising Therapies for Cutaneous T-cell Lymphoma Treatment\" \/>\n<meta property=\"og:description\" content=\"Over 25+ leading giants are currently evaluating their lead assets in various stages of clinical development to improve therapeutic space.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-cutaneous-t-cell-lymphoma-treatment\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-11T12:24:55+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-11-11T12:24:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/11\/11174710\/emerging-therapies-for-cutaneous-t-cell-lymphoma-treatment.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Promising Therapies for Cutaneous T-cell Lymphoma Treatment","description":"Over 25+ leading giants are currently evaluating their lead assets in various stages of clinical development to improve therapeutic space.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-cutaneous-t-cell-lymphoma-treatment","og_locale":"en_US","og_type":"article","og_title":"Promising Therapies for Cutaneous T-cell Lymphoma Treatment","og_description":"Over 25+ leading giants are currently evaluating their lead assets in various stages of clinical development to improve therapeutic space.","og_url":"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-cutaneous-t-cell-lymphoma-treatment","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2022-11-11T12:24:55+00:00","article_modified_time":"2022-11-11T12:24:56+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/11\/11174710\/emerging-therapies-for-cutaneous-t-cell-lymphoma-treatment.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":["WebPage","FAQPage"],"@id":"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-cutaneous-t-cell-lymphoma-treatment","url":"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-cutaneous-t-cell-lymphoma-treatment","name":"Promising Therapies for Cutaneous T-cell Lymphoma Treatment","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-cutaneous-t-cell-lymphoma-treatment#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-cutaneous-t-cell-lymphoma-treatment#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/11\/11174710\/emerging-therapies-for-cutaneous-t-cell-lymphoma-treatment.png","datePublished":"2022-11-11T12:24:55+00:00","dateModified":"2022-11-11T12:24:56+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Over 25+ leading giants are currently evaluating their lead assets in various stages of clinical development to improve therapeutic space.","mainEntity":[{"@id":"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-cutaneous-t-cell-lymphoma-treatment#faq-question-1668168417143"},{"@id":"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-cutaneous-t-cell-lymphoma-treatment#faq-question-1668168427312"},{"@id":"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-cutaneous-t-cell-lymphoma-treatment#faq-question-1668168441451"},{"@id":"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-cutaneous-t-cell-lymphoma-treatment#faq-question-1668168451041"}],"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-cutaneous-t-cell-lymphoma-treatment"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-cutaneous-t-cell-lymphoma-treatment#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/11\/11174710\/emerging-therapies-for-cutaneous-t-cell-lymphoma-treatment.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/11\/11174710\/emerging-therapies-for-cutaneous-t-cell-lymphoma-treatment.png","width":772,"height":482,"caption":"emerging-therapies-for-cutaneous-t-cell-lymphoma-treatment"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-cutaneous-t-cell-lymphoma-treatment#faq-question-1668168417143","position":1,"url":"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-cutaneous-t-cell-lymphoma-treatment#faq-question-1668168417143","name":"What is Cutaneous T-cell lymphoma?\u00a0","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Cutaneous T-cell lymphoma (CTCL) is a rare type of blood cancer. It begins in a type of white blood cell called the T-lymphocyte (T-cell). T-cells help prevent infections and other diseases.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-cutaneous-t-cell-lymphoma-treatment#faq-question-1668168427312","position":2,"url":"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-cutaneous-t-cell-lymphoma-treatment#faq-question-1668168427312","name":"What are the CTCL treatment options?\u00a0","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"CTCL treatment options include topical chemotherapy, radiation therapy, photo-chemotherapy, vitamin A derivatives (retinoids), and chemotherapy. These treatments may be used alone or in varied combinations.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-cutaneous-t-cell-lymphoma-treatment#faq-question-1668168441451","position":3,"url":"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-cutaneous-t-cell-lymphoma-treatment#faq-question-1668168441451","name":"What is the cutaneous T-cell lymphoma market size?\u00a0","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"In the seven major geographies, the cutaneous T-cell lymphoma market size is estimated to be approximately<strong> <\/strong>USD 399 million in 2021.<strong>\u00a0<\/strong>","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-cutaneous-t-cell-lymphoma-treatment#faq-question-1668168451041","position":4,"url":"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-cutaneous-t-cell-lymphoma-treatment#faq-question-1668168451041","name":"Are any FDA-approved drugs available in the cutaneous T-cell lymphoma market?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Currently, the FDA-approved drugs available in the cutaneous T-cell lymphoma market include SGX301 (Soligenix), WP1220 (Moleculin Biotech), and Lacutamab (Innate Pharma).","inLanguage":"en-US"},"inLanguage":"en-US"}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/11\/11174710\/emerging-therapies-for-cutaneous-t-cell-lymphoma-treatment-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">CTCL<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">CTCL drugs<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">CTCL Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Cutaneous T Cell Lymphoma Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Cutaneous T-cell Lymphoma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Cutaneous T-cell lymphoma pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Cutaneous T-cell lymphoma therapies<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">CTCL<\/span>","<span class=\"advgb-post-tax-term\">CTCL drugs<\/span>","<span class=\"advgb-post-tax-term\">CTCL Treatment<\/span>","<span class=\"advgb-post-tax-term\">Cutaneous T Cell Lymphoma Treatment<\/span>","<span class=\"advgb-post-tax-term\">Cutaneous T-cell Lymphoma<\/span>","<span class=\"advgb-post-tax-term\">Cutaneous T-cell lymphoma pipeline<\/span>","<span class=\"advgb-post-tax-term\">Cutaneous T-cell lymphoma therapies<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 3 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on Nov 11, 2022","modified":"Updated on Nov 11, 2022"},"absolute_dates_time":{"created":"Posted on Nov 11, 2022 5:54 pm","modified":"Updated on Nov 11, 2022 5:54 pm"},"featured_img_caption":"emerging-therapies-for-cutaneous-t-cell-lymphoma-treatment","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/19667","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=19667"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/19667\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/19670"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=19667"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=19667"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=19667"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=19667"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=19667"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}